With the rise of CRISPR technology, we are nearing an age of personalized therapies across mass populations. Leaders in life sciences can protect their competitive advantage by preparing for disruption now.
David Wollenberg | February 22, 2017
The human genome, encoded as DNA, encompasses over three billion chemical base pairs. Ten years ago, sequencing a single genome could cost millions of dollars; soon, it will be possible for under $100. This price tag will continue to fall, eventually putting the cost of sequencing in the same range as a flu shot.
Genetic information gives us more insight each day. It helps us understand how genotypes lead to phenotypes and how genetic defects or mutations can lead to cancer, high cholesterol, and other maladies. We are well on our way to predicting how a specific mechanism of action will work on a specific patient—or how likely an individual is to develop various diseases.
This information is valuable, but it becomes truly disruptive in combination with another recent innovation—easy and affordable genome editing through CRISPR technology.